** Fertility benefits management firm Progyny's shares fall 18.6% to $14

** Earlier in the session, PGNY hit $13.78 — lowest since its debut in Oct 2019

** Co forecasts annual rev of $1.135 bln to $1.150 bln, lower than previous expectation of $1.17 bln to $1.20 bln

** Forecasts FY adj. EPS between $1.54 and $1.57 vs earlier est of $1.53 to $1.61

** Expects Q4 rev of $266.2 mln to $281.2 mln and adj. EPS of 31 cents to 35 cents

** Co reported Q3 rev of $286.63 mln, missing est of $296.88 mln - LSEG

** Co says customers took longer to progress through their treatments, and so, took fewer treatments overall

** At least 4 brokerages cut PT on stock

** Leerink Partners cuts PT to $17 from $21, says biggest concern remains how visibility into the business remains challenged

** BofA Global Research cuts PT to $21 from $22

** Including session's move, stock down 62.3% YTD

(Reporting by Sukriti Gupta in Bengaluru)

((Sukriti.Gupta@thomsonreuters.com;))